ES2253810T3 - Uso de r-aines para la prevencion de la enfermedad de alzheimer. - Google Patents

Uso de r-aines para la prevencion de la enfermedad de alzheimer.

Info

Publication number
ES2253810T3
ES2253810T3 ES98908904T ES98908904T ES2253810T3 ES 2253810 T3 ES2253810 T3 ES 2253810T3 ES 98908904 T ES98908904 T ES 98908904T ES 98908904 T ES98908904 T ES 98908904T ES 2253810 T3 ES2253810 T3 ES 2253810T3
Authority
ES
Spain
Prior art keywords
flurbiprofen
nsaid
salt
drug
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98908904T
Other languages
English (en)
Spanish (es)
Inventor
William J. Wechter
John D. Mccracken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/814,490 external-priority patent/US6160018A/en
Application filed by Loma Linda University filed Critical Loma Linda University
Application granted granted Critical
Publication of ES2253810T3 publication Critical patent/ES2253810T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES98908904T 1997-03-10 1998-03-04 Uso de r-aines para la prevencion de la enfermedad de alzheimer. Expired - Lifetime ES2253810T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/814,490 US6160018A (en) 1995-03-13 1997-03-10 Prophylactic composition and method for alzheimer's Disease
US814490 1997-03-10

Publications (1)

Publication Number Publication Date
ES2253810T3 true ES2253810T3 (es) 2006-06-01

Family

ID=25215202

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98908904T Expired - Lifetime ES2253810T3 (es) 1997-03-10 1998-03-04 Uso de r-aines para la prevencion de la enfermedad de alzheimer.

Country Status (9)

Country Link
EP (2) EP0966277B1 (enExample)
JP (1) JP2001514655A (enExample)
AT (2) ATE311865T1 (enExample)
AU (1) AU6682298A (enExample)
CA (1) CA2283255C (enExample)
DE (2) DE69832695T2 (enExample)
DK (1) DK0966277T3 (enExample)
ES (1) ES2253810T3 (enExample)
WO (1) WO1998040061A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163986B1 (es) * 1999-07-13 2003-02-16 Menarini Lab Acidos-alfa-arilpropionicos y arilaceticos como inhibidores de la ciclooxigenasa-ii.
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
EP1551384A4 (en) * 2002-10-07 2008-04-09 Encore Pharmaceuticals Inc R-NSAID ESTERS AND ITS USE
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2008149181A1 (en) 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
WO2010065936A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
CN104540504A (zh) 2012-01-18 2015-04-22 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
EP3022560B1 (en) 2013-07-11 2020-09-02 University of North Texas Health Science Center at Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
JP6364488B2 (ja) 2013-11-26 2018-07-25 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ 認知欠損を治療するための個別化医療的手法
AU2019209792B2 (en) * 2018-01-18 2025-08-14 University Of North Texas Health Science Center At Fort Worth Companion diagnostic for NSAIDs and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
US20230038360A1 (en) * 2019-12-20 2023-02-09 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
FR2687915B1 (fr) * 1992-02-28 1995-05-05 Rhone Poulenc Rorer Sa Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r).
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen

Also Published As

Publication number Publication date
ATE311865T1 (de) 2005-12-15
DE69841267D1 (de) 2009-12-10
ATE446748T1 (de) 2009-11-15
AU6682298A (en) 1998-09-29
EP1642575B1 (en) 2009-10-28
CA2283255A1 (en) 1998-09-17
EP1642575A1 (en) 2006-04-05
DE69832695T2 (de) 2006-09-14
EP0966277B1 (en) 2005-12-07
DK0966277T3 (da) 2006-03-27
JP2001514655A (ja) 2001-09-11
DE69832695D1 (de) 2006-01-12
WO1998040061A1 (en) 1998-09-17
CA2283255C (en) 2007-01-02
EP0966277A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
US6160018A (en) Prophylactic composition and method for alzheimer's Disease
US5955504A (en) Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) Method and composition for treating cystic fibrosis
ES2253810T3 (es) Uso de r-aines para la prevencion de la enfermedad de alzheimer.
US7074826B2 (en) R-NSAID esters and their use
EP1143958B1 (en) Pharmaceutical composition and use of rnsaid for treating inflammation
JP7262118B2 (ja) 医薬組成物およびその使用
JP2005526786A (ja) Ｄｍｘａａとｎｓａｉｄの抗癌的組み合わせ
JPH07507057A (ja) 解熱鎮痛方法および光学的に純粋なｒ（‐）ケトプロフェンを含有する組成物
CN109152758A (zh) 使用依氟鸟氨酸及其类似物和衍生物来治疗包括胶质瘤的癌症的组合物和方法
Vane et al. The history of anti-inflammatory drugs and their mechanism of action
ES2280196T3 (es) Utilizacion de r-acidos arilpropionicos para la preparacion de medicamentos destinados al tratamiento de enfermedades en seres humanos y animales, sobre las que se puede influir terapeuticamente mediante la inhibicion de la activacion de nf-kb.
AU2004222809B2 (en) Pharmaceutical Composition and Method for Treatment of Inflammation
WO2023146846A1 (en) Use of non-steroidal anti-inflammatory compounds for treatment of inflammation
WO2024171073A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
VANE et al. 1 The history of anti-inflammatory drugs and their mechanism of